Microbial secondary metabolites as inhibitors of pharmaceutically important transferases and oxidoreductases

1. Holková I., Bezáková L., Vanko M., Bilka F., Obložinský M.: Lipoxygenázy a ich význam v biochemických procesoch v rastlinných organizmoch. Chem. Listy 2009; 103, 475–495.

2. Chen X., Yang Y., Ma B., Zhang S., He M., Gui D., Hussain S., Jing Ch., Zhu Ch., Yu Q., Liu Y.: Design and synthesis of potent and selective aldose reductase inhibitors based on pyridylthiadiazine scaffold. Eur. J. Med. Chem. 2011; 46, 1536–1544.

3. Alexiou P., Pegklidou K., Chatzopoulou M., Nicolaou I., Demopoulos V. J.: Aldose reductase enzyme and its implication to major health problems of the 21(st. century. Curr. Med. Chem. 2009; 16, 734–752.

4. Oyama T., Miyasita Y., Watanabe H., Shirai K.: The role of polyol pathway in high glucose-induced endothelial cell damages. Diabetes Res. Clin. Pract. 2006; 73, 227–234.

5. Fujita T., Funako T., Hayashi H.: 8-Hydroxydaidzein, an Aldose Reductase Inhibitor form Okara Fermented with Aspergillus sp. HK-388. Biosci. Biotechnol. Biochem. 2004; 68, 1588–1590.

6. Tai S. S.-K., Lin Ch.-G. , Wu M.-H., Chang T.-S.: Evaluation of Depigmenting Activity by 8-Hydroxydaidzein in Mouse B16 Melanoma Cells and Human Volunteers. Int. J. Mol. Sci. 2009; 10, 4257–4266.

7. Xu B.-J., Jia X.-Q., Gu L.-J., Sung Ch.-K.: Review on the qualitative and quantitative analysis of the mycotoxin citrinin. Food Contr. 2006; 17, 271–285.

8. Sankawa, U., Ebizuka, Y., Noguchi, H., Isikawa, Y., Kitaghawa, S., Yamamoto, Y., Kobayashi, T., Iitak, Y.: Biosynthesis of citrinin in Aspergillus terreus. Tetrahedron 1983; 39, 3583–3591.

9. Hajjaj H., Klaebe A., Loret M., Goma G., Blanc, P. J., Francois J.: Biosynthetic Pathway of Citrinin in the Filamentous Fungus Monascus ruber as Revealed by 13C Nuclear Magnetic Resonance. Appl. Environ. Microbiol. 1999; 65, 311–314.

10. Devi P., D`Souza, L., Kamat, T., Rodrigues, C., Naik, Ch. G.: Batch culture fermentation of Penicillium chrysogenum and a report on the isolation, purification and antibiotic activity of citrinin. Indian J. Mar. Sci. 2009; 38, 38–44.

11. Dong Y., Yang J., Ren X., Zhang H., He J.: New aldose reductase inhibitors N99-596 A and B from Streptomyces. J. Antibiot. 2005; 58, 737–739.

12. Deruiter J., Jacyno J. M., Cutler H. G., Davis R. A.: Studies on aldose reductase inhibitors from fungi. 2. Moniliformin and small ring analogs. J. Enzym. Inhib. 1993; 7, 249–256.

13. Chidananda C., Rao L. J. M., Sattur A. P.: Sclerotiorin, from Penicillium frequentans, a potent inhibitor of aldose reductase. Biotechnol. Lett. 2006; 28, 1633–1636.

14. Rao S. K. C., Divakar S., Naveen Babu K., Appu Rao A. G., Karanth N. G., Sattur A. P.: Nigerloxin, a novel inhibitor of aldose reductase and lipoxygenase with free radical scavenging activity from Aspergillus niger CFR-W-105. J. Antibiot. 2003; 56, 789–793.

15. Rao K. C. S., Divakar S., Srinivas M., Babu K. N., Karanth N. G., Sattur A. P.: Asperaldin, a new aldose reductase inhibitor from Aspergillus niger CFR-1046. I. Fermentation, isolation and characterization. J. Antibiot. 2003; 56, 173–176.

16. Nishikawa M., Tsurumi Y., Murai H., Yoshida K., Okamoto M., Takase S., Tanaka H., Hirota H., Hashimoto M., Kohsaka M.: WF-2421, a new aldose reductase inhibitor produced from a fungus, Humicola grisea. J. Antibiot. 1991; 44, 130–135.

17. Sun W. S., Lee H. S., Park J. M., Kim S. H., Yu J. H., Kim J. H.: YUA001, a novel aldose reductase inhibitor isolated from alkalophilic Corynebacterium sp. YUA25 II. Chemical modification and biological activity. J. Antibiot. 2001; 54, 827–830.  

18. McTaggert S. J.: Isoprenylated proteins. Cell. Mol. Life Sci. 2006, 63, 255-267.

19. Wang C. Y., Liu P. Y., Liao J. K.: Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends. Mol. Med. 2008; 14, 37–44.

20. Dudakovic A., Wiemer A. J., Lamb K. M., Vonnahme L. A., Dietz S. E., Hohl R. J.: Inhibition of geranylgeranyl diphosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzymes. J. Pharmacol. Exp. Therapeut. 2008; 324, 1028–1036.

21. Konya A., Jekkel A., Sutö J., Salat J.: Optimization of compactin fermentation. J. Ind. Microbiol. Biotechnol. 1998; 20, 150–152.

22. Shaligram N. S., Singh S. K., Singhal R. S., Szakacs G., Pandey A.: Effect of precultural and nutritional parameters on compactin production by solid-state fermentation. J. Microbiol. Biotechnol. 2009; 19, 690–697.

23. Garrett I. R., Gutierrez G. E., Rossini G., Nyman J., McCluskey B., Flores A., Mundy, G. R.: Locally delivered lovastatin nanoparticles enhance fracture healing in rats. J. Orthop. Res. 2007; 25, 1351–1357.

24. Crick D. C., Andres D. A., Danesi R., Macchia M., Waechter C. J.: Geranylgeraniol overcomes the block of cell proliferation by lovastatin in C6 glioma cells. J. Neurochem. 1998; 70, 2397–2404.

25. Xia Z., Tan M. M., Wong W. W. L., Dimitroulakos J., Minden M. D., Penn L. Z.: Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 2001; 15, 1398–1407.

26. Seenivasan A., Subhagar S., Aravindan R., Viruthagiri T.: Microbial production and biomedical applications of lovastatin. Indian J. Pharmaceut. Sci. 2008, 70, 701–709.

27. Manzoni M., Rollini M.: Biosynthesis and biotechnological production of statins by filamentous fungi. Appl. Microbiol. Biotechnol. 2002; 58, 555–564.

28. Alberts A. W., Chen J., Kuron G., Hunt V., Huff J., Hoffman C., Rothrock J., Lopez M., Joshua H., Harris E., Patchett A., Monaghan R., Currie S., Stapley E., Albers-Schonberg G, Hensens O., Hirshfield J., Hoogsteen K., Liesch J., Springer J.: Mevinolin: A Highly Competitive Inhibitor of Hydroxymethylglutaryl-Coenzyme A Reductase and a Cholesterol Lowering Agent. Proc. Natl. Acad. Sci. USA 1980; 77, 3957–3961.

29. Yan J., Xu Y., Zhu C., Zhang L., Wu A., Yang Y., Xiong Z., Deng C., Huang X. F., Yenari M. A., Yang Y. G., Ying W., Wang Q.: Simvastatin Prevents Dopaminergic Neurodegeneration in Experimental Parkinsonian Models: The Association with Anti-Inflammatory Responses. PLoS ONE 2011, 6, e20945. http://www.plosone.org.

30. Kűhn H., Belkner J., Zaiss S., Fährenklemper T., Wohlfeil S.: Involvement of 15-lipoxygenase in early stages of atherogenesis. J. Exp. Med. 1994; 179, 1903–1911.

31. Kelavkar U. P., Nixon J. B., Cohen C., Dillehay D., Eling T. E., Badr K. F.: Overexpression of 15-lipoxygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis. Carcinogenesis 2002; 22, 1765–1773.

32. Jefferson Jr. W. E.: The isolation and characterization of asperenone, a new phenylpolyene from Aspergillus niger. Biochemistry 1967; 6, 3479–3484.

33. Yu J., Tamura G., Takahashi N., Arima K.: Asperyellone, a new yellow pigment of Aspergillus awamori and Aspergillus niger. Agr. Biol. Chem. 1967; 31, 831–836.

34. Ayer W. A., Muir D. J., Chakravarty P.: Phenolic and other metabolites of Phellinus pini, a fungus pathogenic to pine. Phytochemistry 1996; 42, 1321–1324.

35. Rao K. C., Divakar S., Appu Rao A. G., Karanth N. G., Suneetha W. J., Krishnakantha T. P., Sattur A. P.: Asperenone: an inhibitor of 15-lipoxygenase and of human platelet aggregation from Aspergillus niger. Biotechnol. Lett. 2002; 24, 1967–1970.

36. Chidananda C., Kumar C. M., Sattur A. P.: Strain improvement of Aspergillus niger for the enhanced production of asperenone. Indian. J. Microbiol. 2008; 48, 274–278.

37. Chidananda C., Sattur A. P.: Sclerotiorin, a novel inhibitor of lipoxygenase from Penicillium frequentans. J. Agr. Food Chem. 2007; 55, 2879–2883.

38. Lucas E. M. F., Machado Y., Ferreira A. A., Dolabella L. M. P., Takahashi J. A.: Improved production of pharmacologically-active sclerotiorin by Penicillium sclerotiorum. Trop. J. Pharmaceut. Res. 2010; 9, 365–371.

39. Rao S. K. C., Divakar S., Naveen Babu K., Appu Rao A. G., Karanth N. G., Sattur A. P.: Nigerloxin, a novel inhibitor of aldose reductase and lipoxygenase with free radical scavenging activity from Aspergillus niger CFR-W-105. J. Antibiot. 2003; 56, 789–793.

40. Hasan H. A. H.: Production and Determination of Nigerloxin by Aspergillus niger. Int. J. Agr. Biol. 2007; 9, 315–318.

41. Chakradhar D., Javeed S., Sattur P. A.: Studies on the production of nigerloxin using agro-industrial residues by solid-state fermentation. J. Ind. Microbiol. Biotechnol. 2009; 36, 1179–1187.

42. Esposito F., Kharlamova T., Distinto S., Zinzula L., Cheng Y. C., Dutschman G., Floris G., Markt P., Corona A., Tramontano E.: Alizarine derivatives as new dual inhibitors of the HIV-1 reverse transcriptase-associated DNA polymerase and RNase H activities effective also on the RNase H activity of non-nucleoside resistant reverse transcriptases. FEBS J. 2011; 278, 1444–1457.

43. Kaul A., Maltese W. A.: Killing of Cancer Cells by the Photoactivatable Protein Kinase C Inhibitor, Calphostin C, Involves Induction of Endoplasmic Reticulum Stress. Neoplasia 2009; 11, 823–834.

44. Isel C., Ehresmann Ch., Marquet R.: Initiation of HIV Reverse Transcription. Viruses 2010; 2, 213–243.

45. Lai M. T., Munshi V., Touch S., Tynebor R. M., Tucker T. J., McKenna P. M., Williams T. M., DiStefano D. J.: Antiviral Activity of MK-4965, a Novel Nonnucleoside Reverse Transcriptase Inhibitor. Antimicrob. Agents Chemother. 2009; 53, 2424–2431.

46. Demain A. L., Somkuti G. A., Hunter-Cavera J. C., Rossmoore H. W.: Novel microbial products for medicine and agriculture. Netherlands: Elsevier, 1989.

47. Davidson R. N., Boerb M., Ritmeijerb K.: Paromomycin. Trans. Roy. Soc. Trop. Med. Hyg. 2009; 103, 653–660.

48. Kitahara N., Haruyama H., Hata T., Takahashi S.: The structures of thielavins A, B and C. Prostaglandin synthetase inhibitors from fungi. J. Antibiot. 1983; 36, 599–600.

49. Sakemi S., Hirai H., Ichiba T., Inagaki T., Kato Y., Kojima N., Nishida H., Parker J. C., Saito T., Tonai-Kachi H., Volkenburg M. A., Yoshikawa N., Kojima Y.: Thielavins as glucose-6-phosphatase (G6Pase. inhibitors: producing strain, fermentation, isolation, structural elucidation and biological activities. J. Antibiot. 2002; 55, 941–951.

50. Mani N., Sanchet P., Jiang Z. D., McNaney C., DeCenzo M., Knighti B., Stankis M., Kuranda M., Rothenstein D. M.: Screening systems for detecting inhibitors of cell wall transglycosylation in Enterococcus. J. Antibiot. 1998; 51, 471–479.

51. Chen J. L.-Y., Sperry J., Ip, N. Y., Brimble M. A.: Natural products targeting telomere maintenance. Med. Chem. Commun. 2011; 2, 229–245.

52. Rao K. V., Cullen W. P.: Streptonigrin, an antitumour substance. I. Isolation and characterization. Antibiot. Annu. 1959; 7, 950–953.

53. Société des usines chimiques de Rhône-Poulenc, GB Patent 872261, 1961, Chem. Abstr. 1961; 55, 25158a.

54. Kudrina E. S., Ol’khovatova O. L., Murav’eva L. I., Gauze G. F.: Systematic position and variability of the producent of antitumor antibiotic bruneomycin. Antibiotiki 1966; 11, 400–405.

55. Brazhnikova M. G., Ponomarenko I. N., Kovsharova E. B., Kruglyak E. B., Proshlyakova V. V.: Study of bruneomycin formed by Actinomyces albus var. bruneomycini and its identification with streptonigrin. Antibiotiki 1968; 13, 99–102.

56. Bolzán A. D., Bianchi M. S.: Genotoxicity of streptonigrin: a review. Mutat. Res. Rev. Mutat. Res. 2001; 488, 25–37.

57. Mesak L. R., Qi S., Villanueva I., Miao V., Davies J.: Staphylococcus aureus promoter-lux reporters for drug discovery. J. Antibiot. (Tokyo) 2010; 63, 492–498.

58. Serova M., Ghoul A., Benhadji K. A., Cvitkovic E., Faivre S., Calvo F., Lokiec F., Raymond E.: Preclinical and clinical development of novel agents that target the protein kinase C family. Semin. Oncol. 2006; 33, 466–478.

59. Martiny-Baron G., Fabbro D.: Classical PKC isoforms in cancer. Pharmacol. Res. 2007; 55, 477–486.

60. Mackay H. J., Twelves C. J.: Targeting the protein kinase C family: are we there yet? Nat. Rev. Canc. 2007; 7, 554–562.

61. Kaul A., Maltese W. A.: Killing of Cancer Cells by the Photoactivatable Protein Kinase C Inhibitor, Calphostin C, Involves Induction of Endoplasmic Reticulum Stress. Neoplasia 2009; 11, 823–834.

62. Kobayashi E., Ando K., Nakano H., Iida T., Ohno H., Morimotot M., Tamaoki T.: Calphostins (UCN - 1028., novel and specific inhibitors of protein kinase C. I. Fermentation, isolation, physico-chemical properties and biological activities. J. Antibiot. 1989; 42, 1470–1474.

63. Olivo M., Ali-Seyed M.: Apoptosis signalling mechanisms in human cancer cells induced by calphostin-PDT. Int. J. Oncol. 2007; 30, 537–548.

64. Chiarini A., Whitfield J. F., Pacchiana R., Armato U., Dal Pra I.: Photoexcited calphostin C selectively destroys nuclear lamin B1 in neoplastic human and rat cells – a novel mechanism of action of a photodynamic tumor therapy agent. Biochim. Biophys. Acta 2008; 1783, 1642–1653.

65. Guo B., Hembruff S. L., Villeneuve D. J., Kirwan A. F, Parissenti A. M.: Potent killing of paclitaxel- and doxorubicin-resistant breast cancer cells by calphostin C accompanied by cytoplasmic vacuolization. Breast Canc. Res. Treat. 2003; 82, 125–141.

66. Trindade-Silva A. E., Lim-Fong G. E., Sharp K. H., Haygood M. G.: Bryostatins: biological context and biotechnological prospects. Curr. Opin. Biotechnol. 2010; 21, 834–842.

67. Wender P. A., Baryza J. L., Brenner S. E., DeChristopher B. A., Loy B. A., Schrier A. J., Verma V. A.: Design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity. Proc. Natl. Acad. Sci. 2011; 108, 6721–6726 (http://www.pnas.org).

68. Gully Ch. P., Zhang F., Chen J., Yeung J. A., Velazquez-Torres G., Wang E., Yeung S.-Ch. J., Lee M.-H.: Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol. Canc. 2010; 9(42). http://www.molecular-cancer.com)

69. Ayer S. W., McInnes A. G., Thibault P., Walter J. A., J. L. Doull Parnell, T., Vining L. C.: Jadomycin, a novel 8i/-benz[6]oxazolo[3,2-/]phenanthridine antibiotic from Streptomyces venezuelaeISP5230. Tetrahedron Lett. 1991; 32, 6301–6304.

70. Fu D.-H., Jiang W., Zheng J.-T., Zhao G.-Y., Li Y., Yi H., Li Z.-R., Jiang J.-D., Yang K.-Q., Wang Y., Si S.-Y.: Jadomycin B, an Aurora-B kinase inhibitor discovered through virtual screening. Mol. Canc. Therapeut. 2008; 7, 2386–2393.

71. Jakeman D. L., Bandi S., Graham C. L., Reid T. R., Wentzell J. R., Douglas S. E.: Antimicrobial Activities of Jadomycin B and Structurally Related Analogues. Antimicrob. Agents Chemother. 2009; 53, 1245–1247.

72. Aly A. H., Debbab A., Edrada-Ebel R. A., Müller W. E. G., Kubbutat M. H. G., Wray V., Ebel R., Proksch P.: Protein kinase inhibitors and other cytotoxic metabolites from the fungal endophyte Stemphylium botryosum isolated from Chenopodium album. Mycosphere 2010; 1, 153–162.